Articles Archives - Page 141 of 626

WednesdayAug 24, 2022 9:00 am

Laredo Oil Inc. (LRDC) Partners with Dawson James Securities to Focus on Future Growth

Dawson James brings 20 years of investment banking experience that will enhance LRDC presence in public financial markets Financial advisory agreement outlines valuable advice, consultations regarding uplisting, business and financial planning, corporate organization and structure, and more Laredo Oil is an oil exploration, production company primarily engaged in acquisition and exploration efforts for mineral properties Uplisting to a higher exchange can bring significant advantages to companies, and Laredo Oil (OTC: LRDC) is eyeing that possibility and making strategic moves in that direction. Laredo, an exploration and production company specializing in conventional and enhanced oil recovery (“EOR”) techniques targeting mature and…

TuesdayAug 23, 2022 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Quantum Computing Technology Is Providing Solutions to Complex Problems Experienced Across Multiple Industries

D-Wave is the only provider building both annealing and gate-model quantum computers that offers solutions to complex problems that classical computers may not be able to process The company provides value through practical applications for problems across logistics, artificial intelligence, materials science, drug discovery, scheduling, fraud detection, financial modeling, and more. D-Wave is hosting the upcoming Qubits conference (October 11-13, 2022), one of quantum industry’s premiere and informative quantum for business events, with speakers featuring quantum pioneers including Mastercard, Johnson & Johnson, Fidelity, Schlumberger, and more D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems and software solutions, is…

TuesdayAug 23, 2022 9:45 am

Inflation Reduction Act; Going Solar is the Next Viral Housing Trend

The newly passed Inflation Reduction Act provides a litany of incentives for homeowners to transition to renewable energies GeoSolar Technologies SmartGreen(TM) package uses leading edge solar, geothermal and air quality technologies to maximize home efficiency with minimal environmental impact GeoSolar’s process is an end-to-end solution to help people better understand all the incentives available and financing options to realize a solid ROI and eventually generate clean, free energy The passage of the “anti-inflation” bill this month should conjure up a lot more thoughts than just talking points about the bill’s name. Fact is, the landmark climate and healthcare bill, no…

TuesdayAug 23, 2022 9:00 am

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Leverages Lightning Network to Facilitate Micropayments Across 17 Countries

LQwD’s BTC capacity on The Lightning Network exceeds 30 BTC with over 300 payment channels operating across 17 countries with plans to expand to 24 countries by the end of the current quarter The debut of Bitcoin occurred during the recession of 2008 by an anonymous individual or group later named “Satoshi Nakamoto” The fractionalized form of bitcoin is named after Nakamoto, with 1 satoshi equivalent to 0.00000001 BTC The cryptocurrency market value is expected to reach US $4.94 billion by 2030 LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a financial technology company focused on creating enterprise-grade infrastructure to drive Bitcoin…

MondayAug 22, 2022 11:15 am

DGE 3rd Clinical Trial Agreement Forum to Discuss Important Changes Impacting CTA’S and Remote Monitoring Agreements

Professionals and executives of biopharma and medical device companies are invited to attend DGE’s 3rd Clinical Trial Agreement Forum, a virtual online livestream event, on September 29-30, 2022. The conference will discuss how the evolution of the virtual clinical trial landscape requires flexibility when designing and modifying clinical trial agreements (“CTAs”). Clinical trials have seen many changes with the advent of virtual clinical trials, where telemedicine and remote monitoring are used. Changes that impact the CTAs include incorporating cybersecurity language, more complicated indemnification, complexities of third-party contracting, and an increase in remote monitoring. The conference will provide insights into novel industry…

MondayAug 22, 2022 10:30 am

Correlate Infrastructure Partners Inc. (CIPI), a Driver of Highly Cost-effective Solutions for Energy Use Optimization, Sees Significant Revenue Growth in Q2 2022

Correlate posts significant increase in Q2 revenue from $1,584 in 2021 to $236,690 in 2022 Customer deposits have also increased, from $0 during the same period in 2021 to $1,114,154 in Q2 2022, while operating expenses have grown from $4,937 to $1,444,794 Correlate has attributed the growth to the increased emphasis on commercialization, a shift from previous quarters that focused on product development The company hopes to maintain the current trajectory in performance, mainly banking on helping its commercial customers increase their NOI while also maturing its aggressive acquisition strategy Correlate Infrastructure Partners (OTCQB: CIPI), earlier released its results for…

MondayAug 22, 2022 9:45 am

$4M Investment Provides Capital Injection for FingerMotion Inc. (NASDAQ: FNGR) Mobile Device Protection Strategy in China

New York-based institutional fund manager The Lind Partners has reached an investment agreement with mobile device technology innovator FingerMotion Inc. to provide FingerMotion $4 million that will advance its initiatives FingerMotion is focused on varied initiatives for serving China’s massive mobile device user market, its top priority being the rollout of an AppleCare-similar device protection plan the company expects to be popular with users Company CEO Martin Shen has stated the protection plan service has the highest potential to yield returns on capital investment in the shortest amount of time China has more than 450 million 5G mobile phone users…

MondayAug 22, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial The MAD arm thus far shows that the drug is safe and well tolerated Odyssey expects to report additional MAD results as they become available A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC:…

FridayAug 19, 2022 10:30 am

NECANN 3rd Annual New Jersey Cannabis Convention Brings the East Coast Cannabis Community under One Roof

The NECANN Conference has evolved into the largest conference on the East Coast, attracting cannabis cultivators, traders, regulators, lawmakers, and enthusiasts, from the East Coast and beyond. The 3rd annual New Jersey Cannabis Convention is being held from September 9-10, 2022, in Atlantic City, New Jersey. This is a well-curated event organized by a highly talented team of professionals with desired expertise and experience. They keep in mind the needs and requirements of the cannabis community and bring together investors, young and veteran cannabis and hemp traders, as well as researchers and lawmakers, all in a common forum. After fighting…

FridayAug 19, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Delighted About Well-Received DehydraTECH-CBD Proposals by the FDA; Maintains Late 2022/Early 2023 Target For Complete IND Application

Lexaria’s successful HYPER-H21-2 human clinical study, whose results were announced in the first week of September 2021, laid the groundwork for the company’s patented DehydraTECH(TM)-processed CBD NDA Chris Bunka, the company’s CEO, referred to the results as “statistically significant,” ultimately kickstarting the IND application process with the FDA Lexaria has since received a full written positive response from the FDA on its DehydraTECH-CBD, agreeing to the company’s proposal to pursue the 505(b)(2) NDA regulatory pathway As a result of the favorable FDA response, Lexaria expects to remain on track to file its full IND application, 6-9 months sooner than if…

Site Search

Company Search

Category: Articles